38 related articles for article (PubMed ID: 31138901)
1. Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer.
Türkmen B; Schmitt M; Schmalfeldt B; Trommler P; Hell W; Creutzburg S; Graeff H; Magdolen V
Electrophoresis; 1997 May; 18(5):686-9. PubMed ID: 9194591
[TBL] [Abstract][Full Text] [Related]
2. AT1 receptor A/C1166 polymorphism contributes to cardiac hypertrophy in subjects with hypertrophic cardiomyopathy.
Osterop AP; Kofflard MJ; Sandkuijl LA; ten Cate FJ; Krams R; Schalekamp MA; Danser AH
Hypertension; 1998 Nov; 32(5):825-30. PubMed ID: 9822439
[TBL] [Abstract][Full Text] [Related]
3. Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts.
van Vugt LJ; van den Reek JMPA; Meulewaeter E; Hakobjan M; Heddes N; Traks T; Kingo K; Galluzzo M; Talamonti M; Lambert J; Coenen MJH; de Jong EMGJ
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):112-118. PubMed ID: 31287604
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphisms and gastric cancer risk: a comprehensive review synopsis from meta-analysis and genome-wide association studies.
Tian J; Liu G; Zuo C; Liu C; He W; Chen H
Cancer Biol Med; 2019 May; 16(2):361-389. PubMed ID: 31516756
[TBL] [Abstract][Full Text] [Related]
5. TH17/IL23 cytokine gene polymorphisms in bullous pemphigoid.
Tabatabaei-Panah PS; Moravvej H; Aghaei S; Akbari M; Rajabi S; Kia A; Ebrahimi E; Sadaf Z; Atoon A; Behravesh N; Ludwig RJ; Akbarzadeh R
Mol Genet Genomic Med; 2020 Dec; 8(12):e1519. PubMed ID: 33340282
[TBL] [Abstract][Full Text] [Related]
6. A Multigene-Panel Study Identifies Single Nucleotide Polymorphisms Associated with Prostate Cancer Risk.
Manca MA; Scarpa F; Cossu D; Simula ER; Sanna D; Ruberto S; Noli M; Ashraf H; Solinas T; Madonia M; Cusano R; Sechi LA
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108754
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms in
Islam MR; Aziz MA; Shahriar M; Islam MS
Cancer Control; 2022; 29():10732748221143879. PubMed ID: 36458977
[TBL] [Abstract][Full Text] [Related]
8. [Difference of colon cancer and rectal cancer-from the view of an oncological physician].
Xu JM
Zhonghua Zhong Liu Za Zhi; 2010 May; 32(5):321-3. PubMed ID: 20723426
[No Abstract] [Full Text] [Related]
9. [Predictive marker for the efficacy of FOLFOX treatment in colon cancer (TS, ERCC1 etc)].
Kumamoto K; Ishibashi K; Ishida H
Nihon Rinsho; 2011 Apr; 69 Suppl 3():494-9. PubMed ID: 22214010
[No Abstract] [Full Text] [Related]
10. Interleukin-17A polymorphisms predict the response and development of tolerance to FOLFOX chemotherapy in colorectal cancer treatment.
Bedoui S; Dallel M; Barbirou M; Stayoussef M; Mokrani A; Mezlini A; Bouhaouala B; Almawi WY; Yacoubi-Loueslati B
Cancer Gene Ther; 2020 May; 27(5):311-318. PubMed ID: 31138901
[TBL] [Abstract][Full Text] [Related]
11. Association of interleukin-17A polymorphisms with the risk of colorectal cancer: A case-control study.
Bedoui SA; Barbirou M; Stayoussef M; Dallel M; Mokrani A; Makni L; Mezlini A; Bouhaouala B; Yacoubi-Loueslati B; Almawi WY
Cytokine; 2018 Oct; 110():18-23. PubMed ID: 29689450
[TBL] [Abstract][Full Text] [Related]
12. Identification of Two Subgroups of FOLFOX Resistance Patterns and Prediction of FOLFOX Response in Colorectal Cancer Patients.
Tian S; Wang F; Lu S; Chen G
Cancer Invest; 2021 Jan; 39(1):62-72. PubMed ID: 33258714
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
[TBL] [Abstract][Full Text] [Related]
14. Utility of Serial Transcriptomic Analyses to Characterize the Resistome and to Refine Treatment Selection for Metastatic Colon Cancer: Case Report.
Castro MP; Afshar M; Williams C; Turcat T; Parker D; Gordon E; Zambelli J; McDonald A; Suh C; Baylon S; Biskup S
Clin Colorectal Cancer; 2021 Mar; 20(1):96-99. PubMed ID: 33353848
[No Abstract] [Full Text] [Related]
15. [Individual Dose Adjustment of 5-Fluorouracil Based on Pharmacokinetic Monitoring May Improve the Outcome of FOLFOX for Metastatic Colorectal Cancer].
Muneoka K; Shirai Y; Sasaki M; Sakata J; Kanda J; Wakabayashi H; Wakai T
Gan To Kagaku Ryoho; 2016 Mar; 43(3):323-6. PubMed ID: 27067847
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
